Biologics, Bowel Disease, Bowel Diseases, Inflammatory, CED, Chronic Inflammatory Small Bowel Disease, Colitis, Ulcerative, Tofacitiniib
Conditions
Brief summary
This registry on Tofacitinib and biologics (anti-integrin/anti-TNF) in the treatment of ulcerative colitis (UC) patients in Germany will extend the prospective documentation of safety issues and efficacy in induction and maintenance therapy of Tofacitinib (Xeljanz®) in addition to other biologics used in Germany with a particular interest in predictors of long-term responses and favorable disease outcome or to predict severe side effects caused by therapy with Januskinase(JAK)- inhibitors/biologics.
Detailed description
This is an Investigator-initiated non-randomized, non-interventional observational prospective long- term research (IIR) as part of the normal treatment of UC patients for the safety and efficacy of Tofacitinib / biologic therapies. As of 01st July 2019, UC patients who have been provided Tofacitinib / biologics for UC according the respective label by the treating physician may be prospectively included in an online database by the participating study centers by 31st March 2021. An interim analysis is planned at the end of patients ́ recruitment with respect of the induction phase (week 16) for October 2021 with a first publication of the data in a peer-reviewed journal (e.g., JCC, GUT, UEG Journal). Up to 480 patients (including about 360 UC patients with Tofacitinib and about 120 UC patients with biologics) will be included in the online documentation. A specification to the study centers regarding the group inclusion (patients treated with Tofacitinib (group 1) or a biologics (group 2)) will not be made; this means, each study center can include patients in both groups. The CED Service GmbH assume that approximately 20-30% of Tofacitinib patients will be biologic-naïve UC patients, many of whom will represent early disease patients (\< 2 years after first diagnosis).
Interventions
None listed
Sponsors
Pfizer
Ced Service GmbH
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* Patients with moderate to severe Ulcerative Colitis aged 18-80 years at enrollment * Written informed consent is given
Exclusion criteria
* Malignant disease in history (except for non-melanoma skin cancer) * Any contraindication according to the SmPC of the respective medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| partial Mayo score ≤ 1 plus a bleeding subscore of 0) in the inductionphase (week 16) | 07/01/2019 - 03/31/2023 | The primary endpoint is steroid-free remission (remission: partial Mayo score ≤ 1 plus a bleeding subscore of 0) in the inductionphase (week 16). For this endpoint it will be only captured if there is a current use of steroids at the time of the visit. So the patient will be asked for current steroid use at time of visit at week 16 and if he has received steroids within the last 4 weeks prior to time point of the visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| response: partial Mayo Score reduction of ≥ 3 accompanied by a decrease of at least 30% from baseline and remission: partial Mayo score ≤ 1 plus a bleeding subscore of 0 - Efficacy | 07/01/2019 - 03/31/2023 | Efficacy (response: partial Mayo Score reduction of ≥ 3 accompanied by a decrease of at least 30% from baseline and remission: partial Mayo score ≤ 1 plus a bleeding subscore of 0) of induction therapy (week 8 and 16) and maintenance therapy (months 6 to 24) and efficacy (response and remission) in different subpopulations, e.g. based on a previous biologic therapy or not. |
| hospitalization days via question in questionnaire | 07/01/2019 - 03/31/2023 | Obtaining health economic data in UC patients on Tofacitinib / biologics therapy (hospitalization) |
| occurrence of serious side effects (e.g., death, tumor, tuberculosis, severe infections, or side effects leading to hospitalization) | 07/01/2019 - 03/31/2023 | Online documentation of safety and efficacy in induction and maintenance therapy including the occurrence of serious side effects (e.g., death, tumor, tuberculosis, severe infections, or side effects leading to hospitalization) |
| EQ-5D quality of life | 07/01/2019 - 03/31/2023 | Obtaining health economic data in UC patients on Tofacitinib / biologics therapy (quality of life) |
| early retirement via question in questionnaire | 07/01/2019 - 03/31/2023 | Obtaining health economic data in UC patients on Tofacitinib / biologics therapy (early retirement) |
| psychosocial impairments - EQ-5D | 07/01/2019 - 03/31/2023 | Obtaining data of the course from UC patients with a new therapy (Tofacitinib / biologics) related to treatment strategy and psychosocial impairments |
Countries
Germany
Outcome results
None listed